Switching from Lovenox to Angiomax in patients with acute coronary syndromes without ST elevation undergoing PCI - SWITCH


The goal of the trial was to evaluate the safety of treatment with bivalirudin among patients pre-treated for up to 12 hours with enoxaparin undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome without ST elevation.